Free tool
FAERS Monitor: Parlodel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017962 or its brand name (Parlodel, Bromocriptine Mesylate). Reports on generic versions are filed under their own applications.
Reports
522
Serious
444
85% of reports
Hospitalization
207
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea34
- drug ineffective31
- headache30
- pyrexia29
- vomiting28
- drug exposure during pregnancy25
- neuroleptic malignant syndrome24
- fatigue21
- dizziness20
- tremor19
- blood creatine phosphokinase increased18
- malaise17
- drug interaction16
- dyspnoea16
- off label use16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 30 |
| 2006 | 34 |
| 2007 | 33 |
| 2008 | 37 |
| 2009 | 15 |
| 2010 | 18 |
| 2011 | 62 |
| 2012 | 55 |
| 2013 | 8 |
| 2014 | 9 |
| 2015 | 10 |
| 2016 | 19 |
| 2017 | 20 |
| 2018 | 8 |
| 2019 | 14 |
| 2020 | 4 |
| 2021 | 12 |
| 2022 | 16 |
| 2023 | 24 |
| 2024 | 41 |
| 2025 | 13 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,637 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuroleptic malignant syndromeSignal | 24 | 81.7 | 55.2 | 1,831 |
| drug exposure during pregnancySignal | 25 | 29.6 | 20.2 | 664 |
| blood creatine phosphokinase increasedSignal | 18 | 25.2 | 16.0 | 395 |
| tremorSignal | 19 | 4.6 | 3.0 | 51 |
| drug interactionSignal | 16 | 4.1 | 2.5 | 34 |
| pyrexiaSignal | 29 | 3.4 | 2.4 | 47 |
| vomitingSignal | 28 | 2.4 | 1.7 | 22 |
| headache | 30 | 1.9 | 1.4 | 13 |
| nausea | 34 | 1.7 | 1.3 | 10 |
| dizziness | 20 | 1.6 | 1.1 | 4 |
| malaise | 17 | 1.6 | 1.0 | 3 |
| dyspnoea | 16 | 1.1 | 0.7 | 0 |
| fatigue | 21 | 1.1 | 0.7 | 0 |
| drug ineffective | 31 | 0.9 | 0.7 | 0 |
| off label use | 16 | 0.7 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.